We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Procalcitonin in Hepatocellular Carcinoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01518829
First Posted: January 26, 2012
Last Update Posted: October 1, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Iman Fawzy Montasser, Ain Shams University
  Purpose
the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.

Condition
Hepatocellular Carcinoma

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Role of Procalcitonin in Differantiation Between Bacerial Infection and Non Infectious Inflammation in Febrile Hepatocellular Carcinoma Patients After Locoregional Treatment

Further study details as provided by Iman Fawzy Montasser, Ain Shams University:

Primary Outcome Measures:
  • Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma [ Time Frame: 6months ]

Biospecimen Retention:   Samples Without DNA
Serum

Enrollment: 42
Study Start Date: April 2012
Study Completion Date: January 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Patients with hepatocellular carcinoma
Patients with hepatocellular carcinoma who will undergo locoregional therapy
patients with chronic liver disease
patients with chronic liver disease, as a control group

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
inpatients in tropical medicine department and hepatocellular carcinoma out patient clinic ain shams university
Criteria

Inclusion Criteria:

  1. - Hepatocellular carcinoma patients who will undergo TACE and/or radio-frequency.
  2. - Fever more than 38C after 48 hours post intervention.

Exclusion Criteria:

  1. HCC Patients who does not develop fever after intervention.
  2. Proven infection elsewhere (e.g. UTI, chest infection..)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01518829


Locations
Egypt
Tropical medicine department and hepatocellular carcinoma clinic
Cairo, Egypt
Sponsors and Collaborators
Ain Shams University
Investigators
Principal Investigator: Hisham K Dabbous, professor Tropical medicine department
  More Information

Responsible Party: Iman Fawzy Montasser, Lecturer of Tropical medicine ,Faculty of Medicine,Ain Shams university, Ain Shams University
ClinicalTrials.gov Identifier: NCT01518829     History of Changes
Other Study ID Numbers: HCC and Procalcitonin
First Submitted: January 24, 2012
First Posted: January 26, 2012
Last Update Posted: October 1, 2013
Last Verified: September 2013

Keywords provided by Iman Fawzy Montasser, Ain Shams University:
hepatocellular carcinom
postablation syndrom
procalcitonin

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases


To Top